Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC ZLC491 | 3053716-46-1 | 98.5% | 866.98 | 5 MG
Supplier: Medchemexpress LLC HY1681625MG
ZLC491 is an orally active PROTAC degrader that selectively targets CDK12/CDK13. It induces cereblon- and proteasome-dependent selective degradation of CDK12 and CDK13, inhibiting the transcription and expression of long genes, and mainly acts on a subset of DNA damage response genes. ZLC491 also inhibits the proliferation of various triple-negative breast cancer cells.
- Selectively targets CDK12/CDK13.
- Orally active PROTAC degrader.
- Induces cereblon- and proteasome-dependent degradation.
- Inhibits transcription and expression of long genes.
- Acts on a subset of DNA damage response genes.
- Inhibits proliferation of triple-negative breast cancer cells.
- Exerts synergistic effect when combined with Cisplatin or Olaparib.
- Shows extremely low activity against non-cancer cell lines.
- Oral bioavailability of 46.8%.
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?